One of Genentech Inc.'s best-selling drugs — and the No. 2 cancer drug worldwide — could get some serious competition, signaling a torrent of cheaper-priced biosimilars.
Amgen Inc., which has research-and-development operations in South San Francisco, and Allergan PLC are asking the Food and Drug Administration to approve a biosimilar version of South San Francisco-based Genentech’s tumor-choking Avastin, which is used in a range of cancers, including breast, lung and brain.
